Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3178325 | 1.00 | DGAT1 (0.54) | DGAT1L3MBTL1EPHX2TDP1ALDH1A1 | |
| SCHEMBL3178211 | 1.00 | DGAT1 (0.54) | DGAT1L3MBTL1EPHX2TDP1ALDH1A1 | |
| SCHEMBL3168169 | 0.96 | DGAT1 (0.58) | DGAT1L3MBTL1EPHX2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3168186 | 0.96 | DGAT1 (0.58) | DGAT1L3MBTL1EPHX2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4927632 | 0.83 | L3MBTL1 (0.53) | DGAT1L3MBTL1EPHX2GRM5 | |
| SCHEMBL25793389 | 0.83 | L3MBTL1 (0.53) | DGAT1L3MBTL1EPHX2ALDH1A1GRM5 | |
| SCHEMBL25793395 | 0.83 | L3MBTL1 (0.53) | DGAT1L3MBTL1EPHX2ALDH1A1GRM5 | |
| SCHEMBL4927636 | 0.83 | L3MBTL1 (0.53) | DGAT1L3MBTL1EPHX2GRM5 | |
| SCHEMBL4504302 | 0.82 | ALDH1A1 (0.50) | DGAT1L3MBTL1TDP1ALDH1A1GRM5 | |
| SCHEMBL11224117 | 0.82 | ACE (0.54) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102119047-B | Heteroaryl derivatives as DGAT1 inhibitors | NOVARTIS AG | 2014-09-24 | — | — | CN | disclosed |
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| CN-102119047-A | Heteroaryl derivatives as DGAT1 inhibitors | NOVARTIS AG | 2011-07-06 | — | — | CN | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022513-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885L3MBTL1 1161/4885EPHX2 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.